{"page_content": "Amgen 2018 Responsibility Highlights Report    8BUSINESS ETHICS ENVIRONMENT REPORTING WORKPLACE ACCESS TO MEDICINE COMMUNITY COMMITMENT\nOur Commitment to Patients\nOur commitment to patients extends beyond delivering \ninnovative medicines to creating healthcare solutions \nfor those we serve. It is also reflected in the following \nareas of focus:\n\u2022  Helping patients get access to the medicines  \nthey need\u2014 see the Access to Medicine   \nsection of this report\n\u2022 Investing in Research\n\u2022 Increasing the Value of Healthcare\n\u2022 Listening to the Voice of the Patient\n\u2022 Ensuring Global Patient Safety \nAmgen invests heavily in research and development \nin search of innovative medicines and tools that may \nprovide breakthrough opportunities for medical needs \nthat are currently unmet. We focus on medicines \nmade using biotechnology, and we aim for medicines \nthat make a difference in patients\u2019 lives. We are \ncommitted to breakthrough medicines and growing our \nunderstanding of human genetics, which we believe \ncan meaningfully aid our ability to discover and deliver \nmedicine to control hard-to-treat diseases.Our efforts to increase the value of  \nhealthcare include:\n\u2022  Revolutionizing the way that biologic medicines \ncan be manufactured through our next-generation \nbiomanufacturing technology, making the process \nfaster and less expensive and reducing our \nenvironmental footprint\n\u2022  Building partnerships that share accountability for \nhealth results within the healthcare system and \nproviding options, such as linking the price of our \nmedicines to their performance \n\u2022  Continuing to develop \u201cbiosimilars\u201d\u2014 high-quality,  \nmore affordable versions of existing biologic  \nmedicines\u2014 to treat inflammatory disease and  \ncertain types of cancer\nWe continue to listen to the voice of the patient \nand integrate it into our processes. In October of \nthis year, Amgen convened a gathering of senior \nleaders from nearly 50 organizations representing \nprofessional societies, patient advocacy organizations, \nemployer groups, insurance companies and industry \nin Washington, D.C., for Amgen\u2019s second annual \nStakeholder Summit, Elevating the Patient Voice.  \nThese kinds of interactions ensure that we can  integrate the perspectives of diverse external \nstakeholders into the development and execution  \nof corporate responsibility. \nWe are dedicated to patient safety. The Global Patient \nSafety department serves patients by monitoring \nthe safety of Amgen products (medicine, devices \nand combination products) through the science of \npharmacovigilance. Pharmacovigilance refers to the \nmonitoring, reviewing, evaluating and communicating of \ninformation on the safety of pharmaceutical products.COMMITMENT\nCOMMITMENT\nFOR MORE INFORMATION \nVisit Amgen\u2019s Commitment to Patients   \non www.amgen.com.", "metadata": {"source": "NASDAQ_AMGN_2018.pdf", "page": 7, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}